Go further with cancer screening
进一步进行癌症筛查
Introducing Galleri®, the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test.1
介绍 Galleri®,这是一种首创的多癌症早期检测测试,通过一次血液检测寻找 50 多种癌症共有的信号。
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Galleri 测试不能检测所有癌症信号,也不能在血液中检测到所有癌症。假阳性和假阴性结果确实会发生。
What is the Galleri test?
Galleri 测试是什么?
Galleri redefines what’s possible. Only 5 cancers have recommended screening tests.2 Using Galleri in addition to these tests can increase the chance of finding cancer early, to allow for earlier treatment.1,3
Galleri 重新定义了可能性。只有 5 种癌症有推荐的筛查测试。使用 Galleri 除了这些测试之外,可以增加早期发现癌症的机会,以便进行更早的治疗。
With a single blood test, Galleri screens for a signal shared by multiple cancers that would otherwise go unnoticed.1,4 If a cancer signal is detected, Galleri predicts the tissue type or organ associated with the cancer signal with 88% accuracy* to help guide follow-up diagnostic testing which may include lab work or imaging to confirm cancer.4
通过一次血液检测,Galleri 可以筛查出多种癌症所共有的信号,否则这些信号可能会被忽视。如果检测到癌症信号,Galleri 可以以 88%的准确率预测与该信号相关的组织类型或器官,以帮助指导后续的诊断测试,可能包括实验室检查或影像学检查来确认癌症。
*In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with a "Cancer Signal Detected" test result.
在 PATHFINDER 研究中,对于具有“检测到癌症信号”测试结果的研究参与者中被诊断为癌症的参与者,癌症信号起源(CSO)的预测准确率为 88%。
Who is Galleri for?
Galleri 是为谁设计的?
Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.5 Cancer risk increases for everyone as they age regardless of family history—only 5% to 10% of cancers are inherited.5,6
年龄是癌症的最大风险因素。事实上,与 50 岁以下的人相比,50 岁以上的成年人患癌症的可能性要高 13 倍。无论家族史如何,随着年龄增长,每个人患癌症的风险都会增加——只有 5%到 10%的癌症是遗传的。
The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
Galleri 测试推荐给癌症风险较高的成年人,例如 50 岁或以上的人。
The Galleri test is available by prescription only.
Galleri 测试仅限处方使用。Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
不建议在怀孕、21 岁以下或正在接受积极癌症治疗的人群中使用 Galleri。
Patients 患者
Patients 患者
Patients
I am interested in learning more about the Galleri test
我对了解更多关于 Galleri 测试感兴趣
Healthcare Providers 医疗服务提供者
Healthcare Providers 医疗服务提供者
Healthcare Providers
I am a healthcare provider interested in offering the Galleri test to my patients
我是一名医疗服务提供者,有兴趣为我的患者提供 Galleri 检测
Employers 雇主
Employers 雇主
Employers
I represent an employer interested in offering the Galleri test to my organization’s employees
我代表一家雇主,有兴趣为我所在组织的员工提供 Galleri 测试
Health Systems 健康系统
Health Systems 健康系统
Health Systems
I represent a health system interested in making the Galleri test available to my patient population
我代表一个关注将 Galleri 测试提供给我的患者群体的健康系统
Sign up for more information about Galleri
注册以获取有关 Galleri 的更多信息
Supported by robust clinical data, Galleri sets the standard for multi-cancer early detection
20,000+ individuals participated in large clinical studies1,4
Have more questions?
Please answer the following questions to fill in the appropriate form.
You can also contact us at (833) 694‑2553 or use the chat feature on the bottom-right of this page for additional help.
-
What describes you best?
-
What are you looking for?
-
Fill in the form
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
We care about your privacy. Our Privacy Policy
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806IF: 50.5 Q1 .
US Preventive Services Task Force. Recommendations Cancer. Accessed 7Mar2023. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.
Schrag D, McDonnall CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.
Hubbell E, Venn O, Shanmugam A. Shared Cancer Signal: Evidence from Cross-Training. Presentation at USC Computational Biology Symposium; May 19-21, 2022; Los Angeles, CA.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes -Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.
NIH/National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. Accessed 3Mar2023. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet.
American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Data on file GA-2021-0065.